A comparative study of the anatomy of the sphincter at the duodenal end of the common bile-duct with special reference to species of animals without a gall-bladder

1920 ◽  
Vol 18 (4) ◽  
pp. 355-360 ◽  
Author(s):  
F. C. Mann
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Gall Bladder ◽  
Comparative Study ◽  
Special Reference ◽  
The Common

Efficacy of oxaliplatin, 5 FU and gemcitabine in advanced pancreato-biliary cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15182-15182
Author(s):  
S. Aggarwal ◽  
A. Negi ◽  
N. Banerjee ◽  
T. Buxi ◽  
M. Kumar ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Partial Response ◽  
Gall Bladder ◽  
Progressive Disease ◽  
Unmet Need ◽  
Biliary Cancer ◽  
Upper Limit ◽  
Chemotherapy Protocol ◽  
The Common

15182 Background: The treatment of advanced pancreato-biliary cancer remains an unmet need. The drugs known to be effective are oxaliplatin, gemcitabine. Method: The records of twenty patients suffering with cancers of advanced gall bladder (10), common bile duct (3), ampulle of vater (3) and pancreas (4) were analysed. Twenty patients were treated in the year 2006. Median age was 52 years. The common sites of metastatis were liver (12), lymphnodes (10), peritoneum (4), lungs (1). The patients with normal bilirubin & LFT (< 3 times upper limit of normal) were included. The chemotherapy protocol was given as: oxaliplatin 50 mg, leucovorin 30 mg, and 5FU 500 mg/m2 on day 1, 2, & 3. Gemcitabine was given 800 mg/m2 on day 2, 9, and 16. The cycle was repeated every 4 weeks. Response: The regimen was well tolerated. Pancytopenia requiring G-CSF, delays in drug administration occurred in 70% cases. The response was as follows-partial response 6/20 (30%), stable disease 5/20 (25%), progressive disease 9/20 (45%). The median survival was 5.5 months, four patients completed six cycles of chemotherapy and survival for at least 12 months. Conclusion: Oxaliplatin, 5 FU, gemcitabine and leucovorin is an effective chemo-protocol in advanced pancreato-biliary cancer. However, there is a need to improve upon the existing results. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document